The data support continued development of WTX-124 in NSCLC, melanoma, CSCC, and GEJ adenocarcinoma, and WTX-330 as monotherapy or combination. Watch for next clinical milestones (dose expansion results, partnership or funding events) given the small market cap and cash burn.
Drugs in focus
HOWL drug pipeline →WTX-124
▼ Bearish Named in this press release- Impact
- Phase
- unknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
- Time to market
- Unknown — no approval timeline exists in available sources; multi-year (if ever) from its current stage, and the program's future is clouded by the company's strategic review.
- Next catalyst
- None dated
What to watchWatch the strategic-alternatives process (no defined timeline per the July 31, 2026 Q2 update), WTX-124's fate is likely a sale/partnership or wind-down rather than a clinical binary. Also watch the cash runway: ~$22.0M at June 30, 2026 against ~$13.8M in quarterly operating expenses, with the company guiding to funding into Q2 2027. Repeated Form 144 filings from backers MPM, RA Capital and UBS Oncology and a 10.3% rise in short positions (July 15 settlement) argue against expecting a near-term squeeze.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.01entry
- T+1 · 7d ago −3.96%α −3.59% · $0.9700
- T+5 · 18h ago −1.90%α −0.21% · $0.9908
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Werewolf Therapeutics presented Phase 1/1b data for WTX-124 (IL-2 prodrug) and Phase 1b/2 data for WTX-330 (IL-12 prodrug) at SITC 2026, showing safety and durable antitumor activity in advanced solid tumors. The company aligned with the FDA on a recommended Phase 2 dose of 18 mg IV Q2W for WTX-124. The data support further development in multiple tumor types, but the company remains early-stage with a $49M market cap and no approved products.
Key Facts
- Phase 1/1b trial of WTX-124 reported data from 155 patients; 3 objective responses in monotherapy dose escalation including a durable CR in CSCC.
- Phase 1b/2 trial of WTX-330 reported data from 24 patients; one confirmed PR in gallbladder cancer.
- FDA aligned on WTX-124 RP2D of 18 mg IV Q2W for monotherapy and combination with pembrolizumab.
- Both molecules were administered safely in the outpatient setting with no vascular leak syndrome.
- Market cap is $49M; company has no approved products and is in early clinical development.
Financial Impact
No financial figures provided in the release; company is pre-revenue with $49M market cap.
Risk Factors
- Early-stage clinical data may not predict final results or regulatory approval.
- Company has no approved products and relies on funding; cash runway not disclosed.
- Competition from other IL-2 and IL-12 therapies in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398415 |
Track record
31 reports on HOWL
12 of 16 bullish or bearish reports moved the stock their way by T+5. Best: +51.32% at T+60 after the Apr 27, 2026 report. 13 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.9500 Now $0.9910 +4.32% settles Nov 23
- Nov 13, 20264d ago EFFECT Neutral 4/10 Entry $0.9803 Now $0.9910 +1.09% settles Nov 20
- Nov 10, 20266d ago S-4/A Neutral 5/10 Entry $0.9889 Now $0.9910 +0.21% settles Nov 18
- Nov 9, 20267d ago 425 Neutral 5/10 Entry $0.9700 Now $0.9910 +2.16% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $1.01 to $0.9908 Now $0.9910 −1.88% ▼ −1.90% −0.21% vs SPY
- Oct 26, 202621d ago S-4/A Bearish 5/10 Entry $1.04 to $1.07 Now $0.9910 +4.71% ▼ −2.88% −4.87% vs SPY
- Sep 22, 20267w ago S-4 Bearish 7/10 Entry $0.9894 to $0.9223 Now $0.9910 −0.16% ▲ +6.78% +6.11% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 3/10 Entry $0.9800 to $0.9300 Now $0.9910 +1.12% ▼ −5.10% −4.08% vs SPY
- Aug 21, 202612w ago 425 Bullish 7/10 Entry $0.8740 to $0.9433 Now $0.9910 +13.39% ▲ +7.93% +7.46% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers